{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:01:51Z","timestamp":1776099711480,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:p>\n                    This study aims to compare and analyze the effects of denosumab combined with calcium and vitamin D versus calcium and vitamin D alone on bone remodeling markers and bone mineral density (BMD) in patients with osteoporotic fractures. This single-center retrospective comparative study included patients with osteoporotic fractures admitted between January 2022 and January 2024. According to the treatment regimen, patients were divided into the denosumab group (subcutaneous denosumab every 6 months plus oral calcium and vitamin D supplementation) and the calcium plus vitamin D (CaD) group (oral calcium and vitamin D supplementation only). Propensity score matching was used to balance baseline characteristics, with 60 cases in each group. Bone remodeling markers (\u03b2-isomerized C-terminal telopeptide of type I collagen [\u03b2-CTX], procollagen type I N-terminal propeptide [P1NP], bone-specific alkaline phosphatase, osteocalcin), BMD changes, and safety profiles were compared between the 2 groups before treatment, and at 6 and 12 months after treatment. After treatment, the levels of the bone resorption marker \u03b2-CTX and the bone formation marker P1NP were significantly reduced in the denosumab group, and remained significantly lower than those in the CaD group at all time points (time, group, and interaction effects all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). After 12 months of treatment, BMD increases in the lumbar spine and femoral neck were 8.8% and 7.3% respectively in the denosumab group, significantly higher than in the CaD group (2.6% and 2.2%) (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.01 for both group and interaction effects). Correlation analysis showed that in the denosumab group, the decreases in \u03b2-CTX and P1NP were significantly negatively correlated with BMD improvements in the lumbar spine and femoral neck (\n                    <jats:italic toggle=\"yes\">r<\/jats:italic>\n                    \u2005=\u2005\u20130.33 to \u20130.42,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). The overall incidence of adverse events did not differ significantly between the 2 groups (13.3% vs 8.3%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05), and all events were mild. For patients with osteoporotic fractures, denosumab combined with calcium and vitamin D supplementation is more effective in suppressing bone turnover and improving bone mineral density than calcium and vitamin D alone, without increasing significant safety risks. Bone remodeling markers \u03b2-CTX and P1NP may serve as potential reference indicators for evaluating the therapeutic efficacy of denosumab.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047540","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:00:45Z","timestamp":1772240445000},"page":"e47540","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective comparative study on the effects of denosumab combined with calcium and vitamin D versus calcium and vitamin D alone on bone remodeling markers in patients with osteoporotic fractures"],"prefix":"10.1097","volume":"105","author":[{"given":"Zhijun","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Yan\u2019an Hospital of Traditional Chinese Medicine, Yan\u2019an City, Shaanxi Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengxi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Traumatic Orthopedics, Affiliated Hospital of Yan\u2019an University, Yan\u2019an City, Shaanxi Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9341-0446","authenticated-orcid":false,"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Trauma Repair Surgery, Affiliated Hospital of Yan\u2019an University, Yan\u2019an City, Shaanxi Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis.","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"R2-20260413","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures.","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"key":"R3-20260413","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men.","volume":"152","author":"Haentjens","year":"2010","journal-title":"Ann Intern Med"},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"a031211","DOI":"10.1101\/cshperspect.a031211","article-title":"Regulation of bone metabolism by sex steroids.","volume":"8","author":"Khosla","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(18)30265-1","article-title":"Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis.","volume":"6","author":"Bolland","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R7-20260413","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes.","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R11-20260413","first-page":"117","article-title":"Laboratory aspects and clinical utility of bone turnover markers.","volume":"29","author":"Bhattoa","year":"2018","journal-title":"EJIFCC"},{"key":"R12-20260413","first-page":"97","article-title":"Biochemical markers of bone turnover: part I: biochemistry and variability.","volume":"26","author":"Seibel","year":"2005","journal-title":"Clin Biochem Rev"},{"key":"R13-20260413","first-page":"149","article-title":"Advances in bone turnover markers (PINP and CTX) in optimizing anti-resorptive and anabolic therapies against osteoporosis.","volume":"32","author":"Zhong","year":"2021","journal-title":"Discov Med"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11154-010-9153-1","article-title":"Cellular mechanisms of bone remodeling.","volume":"11","author":"Eriksen","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","article-title":"Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.","volume":"16","author":"Bolognese","year":"2013","journal-title":"J Clin Densitom"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.urolonc.2010.08.007","article-title":"Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.","volume":"30","author":"Saad","year":"2012","journal-title":"Urol Oncol"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2015.05.046","article-title":"New insights into the biology of osteocalcin.","volume":"82","author":"Zoch","year":"2016","journal-title":"Bone"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:02:48Z","timestamp":1776096168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047540","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}